Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Janux Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
JANX
Nasdaq
8731
https://www.januxrx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Janux Therapeutics Inc
Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade
- Mar 22nd, 2024 1:55 pm
Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst
- Mar 20th, 2024 7:44 pm
2 Stocks That Have More Than Tripled This Year: Are They Buys?
- Mar 15th, 2024 1:45 pm
Janux Therapeutics Inc (JANX) Reports Encouraging Clinical Data and Solid Financial Position ...
- Mar 8th, 2024 9:31 pm
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Mar 8th, 2024 9:01 pm
The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark
- Mar 4th, 2024 10:25 am
After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
- Mar 2nd, 2024 11:56 am
5 Stocks That More Than Doubled in February
- Mar 1st, 2024 2:29 pm
Recent Price Trend in Janux Therapeutics, Inc. (JANX) is Your Friend, Here's Why
- Mar 1st, 2024 1:50 pm
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- Feb 29th, 2024 6:22 am
Janux Therapeutics Announces Proposed Public Offering of Common Stock
- Feb 27th, 2024 10:00 pm
Janux Stock Launches 230% On Its 'Significant Opportunity' In Prostate Cancer Treatment
- Feb 27th, 2024 9:04 pm
Janux shares triple on early cancer immunotherapy data
- Feb 27th, 2024 12:15 pm
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
- Feb 26th, 2024 9:05 pm
Janux Therapeutics, Inc. (JANX) Moves 5.6% Higher: Will This Strength Last?
- Feb 21st, 2024 7:39 am
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
- Feb 20th, 2024 1:00 pm
Inovio (INO) Moves 17.4% Higher: Will This Strength Last?
- Feb 12th, 2024 11:25 am
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
- Jan 8th, 2024 2:00 pm
An Intrinsic Calculation For Janux Therapeutics, Inc. (NASDAQ:JANX) Suggests It's 44% Undervalued
- Dec 27th, 2023 12:31 pm
Does Janux Therapeutics, Inc. (JANX) Have the Potential to Rally 205.5% as Wall Street Analysts Expect?
- Dec 1st, 2023 2:55 pm
Scroll